|Mr. Douglas C. Bryant||Chairman & CEO||1.41M||N/A||1958|
|Mr. Robert J. Bujarski J.D.||Pres & COO||770.62k||N/A||1969|
|Ms. Michelle A. Hodges||Gen. Counsel||620.61k||N/A||1960|
|Dr. Werner Kroll Ph.D.||Sr. VP of R&D||758.22k||2.1M||1957|
|Mr. Joseph M. Busky CPA||Chief Financial Officer||N/A||N/A||1968|
|Ruben Argueta||Director of Investor Relations||N/A||N/A||N/A|
|Mr. Michael S. Iskra||Chief Commercial Officer||N/A||N/A||1970|
|Phillip S. Askim||VP, Associate Gen. Counsel & Sec.||N/A||N/A||N/A|
|Dr. Johannes Kehle||Pres of AnDiaTec Division||N/A||N/A||N/A|
|Mr. Rhys de Callier||VP of Strategy & Portfolio Management||N/A||N/A||N/A|
QuidelOrtho Corporation provides various in vitro diagnostics products worldwide. The company's product portfolio covers a range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and clinical and at-home products to detect COVID-19. It provides visually-read lateral flow products in infectious disease and reproductive health; direct fluorescent antibodies in infectious disease and virology; micro-titer production with a focus on bone and complement pathway markets; fluorescent immunoassay products; molecular diagnostic products comprising Savanna, an integrated molecular diagnostic system; immunodiagnostics, clinical chemistry, and integrated testing systems to serve diagnostic labs of all sizes; immunodiagnostic donor screening systems and services that drive blood safety; pre-transfusion testing that automates blood bank workload with software to standardize operations, simplify tasks, and improve productivity; and Ortho Care services and informatics products. The company was founded in 1979 and is headquartered in San Diego, California.
QuidelOrtho Corporation’s ISS Governance QualityScore as of July 1, 2022 is 4. The pillar scores are Audit: 8; Board: 3; Shareholder Rights: 3; Compensation: 4.